Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension Podcast Por  arte de portada

Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension

Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension

Escúchala gratis

Ver detalles del espectáculo

In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.

Subscribe to Eagle’s Eye View

Todavía no hay opiniones